Theoretical structural analyses of tricyclic neuroactive drugs: Quantum pharmacologic descriptors for clustering anticonvulsant, antidepressant, and antipsychotic activities

Journal of Molecular Structure: THEOCHEM

Volumn 467, Issue 1, 1999, Pages 25-30

  Marone, Sandra ^a   Rozas, Isabel ^a   Weaver, Donald F ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

AM1; Anticonvulsants; Antidepressants; Antipsychotics; Geometric effects; Molecular mechanics; Tricyclic drugs

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHLORPROMAZINE; IMIPRAMINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE;

ANTICONVULSANT ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG MECHANISM; DRUG STRUCTURE; MOLECULAR DYNAMICS; PSYCHOPHARMACOLOGY;

EID: 0033165901     PISSN: 01661280     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-1280(98)00468-0     Document Type: Article

References (17)

1. C.P. Taylor, in New Trends in Epilepsy Management, Royal Society of Medicine Services Limited, New York, 1993.
2. M.F. Sugrue, in: S.J. Enn (Ed.), Antidepressants: Neurochemical, Behavioral and Clinical Perspectives, Raven Press, New York, 1981.
3. G.D. Burrows, B.M. Davies, in: G.D. Burrows (Ed.), Antipsychotics, Amsterdam, Elsevier, 1985, p. 4.
4. Wilhelm M. Pharm. J. 214:1975;414.
5. T. Nogrady. Medicinal Chemistry: A Biochemical Approach. Academic Press Inc., New York, 1991, p. 86.
6. Allen F.H., Bellard S., Brice M.D., Cartwright B.A., Doudag A., Higgs H., Hummelink T., Hummelink-Peters B.G., Kennard O., Motherwell W.D.S., Rodgers J.R., Watson D.G. Acta Crystallogr., Sect. B. 35:1979;2331. Cambridge Structural Database:
7. Biograf 3.0, Molecular Simulations Inc., Pasadena, CA, 1991.
8. Mayo S.L., Olafson B.D., Goddard III W.A. J. Phys. Chem. 94:1990;8897.
9. Dewar M.J.S., Zoebisch E.G., Healey E.F., Stewart J.J.P. J. Am. Chem. Soc. 22:1989;384.
10. J.J.P. Stewart, MOPAC 6.0, QCPE 581.
11. V. Loppinet, G. Siest, M. Lahrichi, in: G.Siest (Ed.), Drug Interference and Drug Measurement in Clinical Chemistry, Karger, New York, 1976, p. 58.
12. Post M.L., Kennard O., Horn A.S. Nature. 252:1974;493.
13. Munro S.L., Craik D.J., Andrews P.R. Quant. Struct.-Act. Relat. 6:1987;104.
14. Asscher Y., Avnir D., Rotman A., Agranat I. J. Pharm. Sci. 71:1982;122.
15. Heimstad E., Edvardsen O., Ferrin T.E., Dahl S.G. Eur. Neuropsychopharmacol. 1:1991;127.
16. De Paulis T., Kelder D., Ross S.R., Sternström N.E. Mol. Pharmacol. 14:1978;596.
17. Dahl S.G., Kollman P.A., Shashidhar N.R., Singh U. J. Comput.-Aided Mol. Des. 6:1992;207.